Skip to content
Open in App
Gilead Sciences logo

Gilead Sciences

web2

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes med...

Symbol · GILDUS
Company profile

About

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

FDA approves Trodelvy for first line metastatic triple negative breast cancer

KEY STEP

On June 24, 2026, the FDA approved Trodelvy as first line treatment for adults with unresectable locally advanced or metastatic triple negative breast cancer, including monotherapy for patients not suited to PD L1 inhibitor therapy and use with Keytruda for eligible PD L1 positive disease.

Roadmap reference

FDA approves Bixlenvo for virologically suppressed adults with HIV

KEY STEP

On August 27, 2026, the FDA approved Bixlenvo, a once daily single tablet regimen combining bictegravir and lenacapavir, for adults with HIV who are virologically suppressed. The approval was supported by the Phase 3 ARTISTRY 1 and ARTISTRY 2 studies.

Roadmap reference
People

Company team

DP

Daniel Patrick O'Day

Chairman & CEO

Company leadership profile.

KA

Kelly A. Kramer

Independent Director

Company leadership profile.

HM

Harish M. Manwani

Independent Director

Company leadership profile.

AW

Anthony Welters

Lead Independent Director

Company leadership profile.

JK

Jacqueline K. Barton

Independent Director

Company leadership profile.

SJ

Sandra J. Horning

Independent Director

Company leadership profile.

JJ

Javier J. Rodriguez

Independent Director

Company leadership profile.

JA

Jeffrey A. Bluestone

Independent Director

Company leadership profile.

TW

Ted W. Love

Independent Director

Company leadership profile.

Expert coverage

2 experts evaluated Gilead Sciences.

Orbitrum research

Experts evaluating Gilead Sciences

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment